Posted by Michael Wonder on 12 Mar 2025
Atsena Therapeutics granted US FDA fast track designation for ATSN-201 gene therapy to treat X-linked retinoschisis
12 March 2025 - Marks third FDA designation for ATSN-201, which has also received rare paediatric disease designation and orphan drug designation.
Atsena Therapeutics today announced that the US FDA has granted fast track designation for ATSN-201 for the treatment of X-linked retinoschisis.
